Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

N/A

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 1(4)

N/A(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT02068547Not ApplicableTerminated

Bone Marrow Aspirate Concentration in Posterior Cervical Fusion

Role: collaborator

NCT01074099Phase 1Terminated

Feasibility Study of BMAC Enhanced CABG

Role: lead

NCT01245335Phase 3Completed

Bone Marrow Aspirate Concentrate (BMAC) for Treatment of Critical Limb Ischemia (CLI)

Role: lead

NCT00498069Not ApplicableCompleted

Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)

Role: lead

NCT01299324Phase 1Completed

Retrograde Delivery of BMAC (Bone Marrow Aspirate Concentrate) for Congestive Heart Failure

Role: lead

NCT01061580Phase 1Terminated

BMAC Enhanced Coronary Artery Bypass Grafting (CABG)

Role: lead

NCT00215735Not ApplicableTerminated

Effect of Platelet Concentrate in Treatment of Diabetic Ulcers

Role: lead

NCT00595257Phase 1Completed

Feasability Study of Autologous Bone Marrow Aspirate Concentrate for Treatment of CLI

Role: lead

All 8 trials loaded